Patent US4085398A successfully refreshed from Google Patents.
Patent US4444890A successfully refreshed from Google Patents.
US4444890A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Testing procedure to aid diagnosis of cancer and evaluate the progress of cancer therapy
Assignee: Individual
•
Filing: 1982-02-05
•
Granted: 1984-04-24
•
Expires: 2002-02-05
Abstract
Abstract Antineoplastons are termed a group of plasma, tissue and urinary peptides and amino acid derivatives capable of modulating abnormal tissue growth, such as neoplastic disease. Antineoplastons, when administered to persons with neoplastic disease, have been shown to be effective against several forms of cancer and tumors. A procedure is provided herein for the determination of antineoplaston levels in physiological tissues or fluids, especially plasma and urine. The procedure involves purification of antineoplastons by high performance liquid chromatography on silica gel followed by resolution of antineoplastons by high performance liquid chromatography on sulfonated polystyrene. A quantitative determination of antineoplaston tissue or fluid levels provides valuable data to aid clinical diagnosis of cancer. In addition, the quantitative determination also provides a means for monitoring the efficacy of antineoplastic therapy.
Inventors
- 👤 Stanislaw R. Burzynski
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 22:55
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575
Claims Analysis
Total Claims: 53
Claim 1
Independent Claim
79 words
A method of diagnosing neoplastic disease in a subject suspected of having neoplastic disease comprising: providing a test sample of physiological tissue or fluid obtained from the subject; quantitatively determining the level of antineoplaston within the test sample; comparing the level of antineoplaston of the test sample to a standard antineoplaston level assessed from like tissue or fluid samples obtained from normal subjects unaffected by neoplastic disease, a significant difference in the two levels being indicative of neoplastic disease.
Claim 2
Independent Claim
79 words
A method of diagnosing neoplastic disease in a subject suspected of having neoplastic disease comprising: providing a test sample of physiological tissue or fluid obtained from the subject; quantitatively determining the level of antineoplaston within the test sample; comparing the level of antineoplaston of the test sample to a standard antineoplaston level assessed from like tissue or fluid samples obtained from normal subjects unaffected by neoplastic disease, a significant difference in the two levels being indicative of neoplastic disease.
Claim 3
Dependent Claim
13 words
The method in accordance with claim 1 wherein the test sample is urine.
Claim 4
Dependent Claim
17 words
The method in accordance with claim 1 wherein the test sample is whole blood, plasma or serum.
Claim 5
Dependent Claim
18 words
The method in accordance with claim 1 wherein the level of antineoplaston is determined by chromatographic fractionation means.
Claim 6
Dependent Claim
13 words
The method in accordance with claim 1 wherein the antineoplaston quantitated includes peptides.
Claim 7
Dependent Claim
21 words
The method in accordance with claim 1 wherein the antineoplaston quantitated includes small-sized peptides, having less than ten amino acid residues.
Claim 8
Dependent Claim
14 words
The method in accordance with claim 1 wherein the antineoplaston quantitated includes 3-[N-phenylacetylaminopiperidine]-2, 6-dion.
Claim 9
Dependent Claim
16 words
The method in accordance with claim 1 wherein the antineoplaston quantitated is an amino acid derivative.
Claim 10
Independent Claim
107 words
A method of diagnosing neoplastic disease in a subject suspected of having neoplastic disease comprising: providing a test sample of physiological tissue or fluid obtained from said subjects; extracting from said test sample antineoplaston; fractionating the antineoplaston extract to obtain a plurality of fractions; selecting for further evaluation a fraction containing an antineoplaston substance; quantitatively determining the level of antineoplaston present within the selected fraction; and comparing the level of antineoplaston of the selected fraction to a standard antineoplaston level assessed from like tissue or fluid samples obtained from normal subjects unaffected by neoplastic disease, a significant difference in the two levels being indicative of neoplastic disease.
Claim 11
Independent Claim
107 words
A method of diagnosing neoplastic disease in a subject suspected of having neoplastic disease comprising: providing a test sample of physiological tissue or fluid obtained from said subjects; extracting from said test sample antineoplaston; fractionating the antineoplaston extract to obtain a plurality of fractions; selecting for further evaluation a fraction containing an antineoplaston substance; quantitatively determining the level of antineoplaston present within the selected fraction; and comparing the level of antineoplaston of the selected fraction to a standard antineoplaston level assessed from like tissue or fluid samples obtained from normal subjects unaffected by neoplastic disease, a significant difference in the two levels being indicative of neoplastic disease.
Claim 12
Dependent Claim
14 words
The method in accordance with claim 9 wherein the test sample provided in urine.
Claim 13
Dependent Claim
18 words
The method in accordance with claim 9 wherein the test sample provided is whole blood, plasma or serum.
Claim 14
Dependent Claim
16 words
The method in accordance with claim 9 wherein the fractionation is accomplished by chromatographic fractionation means.
Claim 15
Dependent Claim
17 words
The method in accordance with claim 9 wherein the antineoplaston extracted from the test sample includes peptides.
Claim 16
Dependent Claim
29 words
The method in accordance with claim 9 wherein the antineoplaston extracted from the test sample includes small-sized peptides having less than ten amino acid residues, or amino acid derivatives.
Claim 17
Dependent Claim
14 words
The method in accordance with claim 9 wherein the fraction selected contains 3-[N-phenylacetylaminopiperidine]-2, 6-dion.
Claim 18
Dependent Claim
16 words
The method in accordance with claim 9 wherein the fraction selected contains an amino acid derivative.
Claim 19
Independent Claim
118 words
A method for diagnosing neoplastic disease in a subject suspected of having neoplastic disease comprising: providing a first test sample of physiological tissue or fluid obtained from the subject: providing a second test sample of physiological tissue or fluid obtained from the subject, the second test sample being of a different physiological origin than the first test sample; quantitatively determining the level of antineoplaston within each test sample; evaluating the ratio of antineoplaston levels between the first and second test sample; and comparing the ratio of test samples to a standard antineoplaston ratio associated with like tissue or fluid samples obtained from normal subjects unaffected by neoplastic disease, a significant difference in ratios being indicative of neoplastic disease.
Claim 20
Independent Claim
118 words
A method for diagnosing neoplastic disease in a subject suspected of having neoplastic disease comprising: providing a first test sample of physiological tissue or fluid obtained from the subject: providing a second test sample of physiological tissue or fluid obtained from the subject, the second test sample being of a different physiological origin than the first test sample; quantitatively determining the level of antineoplaston within each test sample; evaluating the ratio of antineoplaston levels between the first and second test sample; and comparing the ratio of test samples to a standard antineoplaston ratio associated with like tissue or fluid samples obtained from normal subjects unaffected by neoplastic disease, a significant difference in ratios being indicative of neoplastic disease.
Claim 21
Dependent Claim
25 words
The method in accordance with claim 17 wherein the first test sample is whole blood, plasma or serum and the second test sample is urine.
Claim 22
Dependent Claim
17 words
The method in accordance with claim 17 wherein the antineoplaston level is determined by chromatographic fractionation means.
Claim 23
Dependent Claim
13 words
The method in accordance with claim 17 wherein the antineoplaston quantitated includes peptides.
Claim 24
Dependent Claim
21 words
The method in accordance with claim 17 wherein the antineoplaston quantitated includes small-sized peptides having less than ten amino acid residues.
Claim 25
Dependent Claim
14 words
The method in accordance with claim 17 wherein the antineoplaston quantitated includes 3-[N-phenylacetylaminopiperidine]-2, 6-dion.
Claim 26
Dependent Claim
16 words
The method in accordance with claim 17 wherein the antineoplaston quantitated is an amino acid derivative.
Claim 27
Independent Claim
80 words
A method of assessing the progress of antineoplastic therapy in a subject diagnosed with neoplastic disease, comprising: providing a test sample of physiological tissue or fluid obtained from the subject; quantitatively determining the level of antineoplaston within the sample; comparing the level of antineoplaston of the test sample to a standard antineoplaston level assessed from like tissue or fluid samples taken from normal subjects unaffected by neoplastic disease, levels substantially the same being indicative of the remission of neoplastic disease.
Claim 28
Independent Claim
80 words
A method of assessing the progress of antineoplastic therapy in a subject diagnosed with neoplastic disease, comprising: providing a test sample of physiological tissue or fluid obtained from the subject; quantitatively determining the level of antineoplaston within the sample; comparing the level of antineoplaston of the test sample to a standard antineoplaston level assessed from like tissue or fluid samples taken from normal subjects unaffected by neoplastic disease, levels substantially the same being indicative of the remission of neoplastic disease.
Claim 29
Dependent Claim
13 words
The method in accordance with claim 24 wherein the test sample is urine.
Claim 30
Dependent Claim
17 words
The method in accordance with claim 24 wherein the test sample is whole blood, plasma or serum.
Claim 31
Dependent Claim
30 words
The method in accordance with claim 24 wherein the test sample provided for antineoplaston quantification is obtained from the subject after steady state level of administered chemotherapeutic agent is retained.
Claim 32
Dependent Claim
18 words
The method in accordance with claim 24 wherein the level of antineoplaston is determined by chromatographic fractionation means.
Claim 33
Dependent Claim
13 words
The method in accordance with claim 24 wherein the antineoplaston quantitated includes peptides.
Claim 34
Dependent Claim
21 words
The method in accordance with claim 24 wherein the antineoplaston quantitated includes small-sized peptides, having less than ten amino acid residues.
Claim 35
Dependent Claim
14 words
The method in accordance with claim 24 wherein the antineoplaston quantitated includes 3-[N-phenylacetylaminopiperidine]-2, 6-dion.
Claim 36
Dependent Claim
15 words
The method in accordance with claim 24 wherein the antineoplaston quantitated includes amino acid derivatives.
Claim 37
Independent Claim
109 words
A method of assessing the progress of antineoplastic therapy in a subject diagnosed with neoplastic disease, comprising: providing a test sample of physiological tissue or fluid obtained from said subjects; extracting from said test sample antineoplaston; fractionating the antineoplaston extract to obtain a plurality of fractions; selecting for further evaluation a fraction containing an antineoplaston substance; quantitatively determining the level of antineoplaston present within the selected fraction; and comparing the level of antineoplaston of the selected fraction to a standard antineoplaston level assessed from like tissue or fluid samples obtained from normal subjects unaffected by neoplastic disease, levels substantially the same being indicative of the remission of neoplastic disease.
Claim 38
Independent Claim
109 words
A method of assessing the progress of antineoplastic therapy in a subject diagnosed with neoplastic disease, comprising: providing a test sample of physiological tissue or fluid obtained from said subjects; extracting from said test sample antineoplaston; fractionating the antineoplaston extract to obtain a plurality of fractions; selecting for further evaluation a fraction containing an antineoplaston substance; quantitatively determining the level of antineoplaston present within the selected fraction; and comparing the level of antineoplaston of the selected fraction to a standard antineoplaston level assessed from like tissue or fluid samples obtained from normal subjects unaffected by neoplastic disease, levels substantially the same being indicative of the remission of neoplastic disease.
Claim 39
Dependent Claim
14 words
The method in accordance with claim 33 wherein the test sample provided is urine.
Claim 40
Dependent Claim
18 words
The method in accordance with claim 33 wherein the test sample provided in whole blood, plasma or serum.
Claim 41
Dependent Claim
16 words
The method in accordance with claim 33 wherein the fractionation is accomplished by chromatographic fractionation means.
Claim 42
Dependent Claim
17 words
The method in accordance with claim 33 wherein the antineoplaston extracted from the test sample includes peptides.
Claim 43
Dependent Claim
29 words
The method in accordance with claim 33 wherein the antineoplaston extracted from the test sample includes small-sized peptides having less than ten amino acid residues, or amino acid derivatives.
Claim 44
Dependent Claim
14 words
The method in accordance with claim 33 wherein the fraction selected contains 3-[N-phenylacetylaminopiperidine]-2, 6-dion.
Claim 45
Dependent Claim
15 words
The method in accordance with claim 33 wherein the fraction selected contains amino acid derivatives.
Claim 46
Independent Claim
122 words
A method of assessing the progress of antineoplastic therapy in a subject diagnosed with neoplastic disease, comprising: providing a first test sample of physiological tissue or fluid obtained from the subject; providing a second test sample of physiological tissue or fluid obtained from the subject, the second test sample being of a different physiological origin than the first test sample; quantitatively determining the level of antineoplaston within each test sample; evaluating the ratio of antineoplaston levels between the first and second test sample; and comparing the ratio of test samples to a standard antineoplaston ratio associated with like tissue or fluid samples obtained from normal subjects unaffected by neoplastic disease, ratios substantially the same being indicative of the remission of neoplastic disease.
Claim 47
Independent Claim
122 words
A method of assessing the progress of antineoplastic therapy in a subject diagnosed with neoplastic disease, comprising: providing a first test sample of physiological tissue or fluid obtained from the subject; providing a second test sample of physiological tissue or fluid obtained from the subject, the second test sample being of a different physiological origin than the first test sample; quantitatively determining the level of antineoplaston within each test sample; evaluating the ratio of antineoplaston levels between the first and second test sample; and comparing the ratio of test samples to a standard antineoplaston ratio associated with like tissue or fluid samples obtained from normal subjects unaffected by neoplastic disease, ratios substantially the same being indicative of the remission of neoplastic disease.
Claim 48
Dependent Claim
25 words
The method in accordance with claim 41 wherein the first test sample is whole blood, serum or plasma and the second test sample is urine.
Claim 49
Dependent Claim
17 words
The method in accordance with claim 41 wherein the antineoplaston level is determined by chromatographic fractionation means.
Claim 50
Dependent Claim
13 words
The method in accordance with claim 41 wherein the antineoplaston quantitated includes peptides.
Claim 51
Dependent Claim
21 words
The method in accordance with claim 41 wherein the antineoplaston quantitated includes small-sized peptides, having less than ten amino acid residues.
Claim 52
Dependent Claim
14 words
The method in accordance with claim 41 wherein the antineoplaston quantitated includes 3-[N-phenylacetylaminopiperidine]-2, 6-dion.
Claim 53
Dependent Claim
16 words
The method in accordance with claim 41 wherein the antineoplaston quantitated includes an amino acid derivative.
References Cited (Backward Citations)
US4270924A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-04-24 | 1987-10-24 | 1988-04-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-04-24 | 1991-10-24 | 1992-04-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-04-24 | 1995-10-24 | 1996-04-24 | $7700.00 | Window Closed / Lapsed |